Gastric Emptying of Solids in Long-Term Nsaid Users: Correlation With Endoscopic Findings and Helicobacter Pylori Status

Kulkarni, Srikanth; Parikh, S S; Shankhpal, P D; Desai, Sapna; Borges, N E; Desai, Sweta; Im, Vora; Kalro, R H

doi:10.1111/j.1572-0241.1999.00863.x

Cited by 12 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…GORD prevalence was also significantly higher in those who use NSAIDs/aspirin. Intake of these classes of drugs have been associated with an increase in gastric acid secretion, reduction in lower oesophageal sphincter pressure, and a delay in gastric emptying, leading to an increase in the risk of GORD [125][126][127] . Moreover, those with a moderate/high intake of spicy food had a significantly higher prevalence of GORD than those with low/no intake, potentially due to a slowed rate of digestion and irritation of the oesophagus caused by intake of spices 128,129 .…”

Section: Discussionmentioning

confidence: 99%

Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis

Nirwan

Hasan

Babar

et al. 2020

Sci Rep

194

148

View full text Add to dashboard Cite

Although gastro-oesophageal reflux disease (GORD) is a common medical complaint, there is currently no consensus on the global prevalence of GORD. The aim of this study was to conduct a systematic review and meta-analysis on GoRD prevalence and risk factors at a global level. MeDLine, eMBASe, CINAHL, Scopus, Cochrane library, and Google Scholar were systematically searched, without language restrictions, for studies on the prevalence and risk factors of GORD. Data were pooled using a random effects model (95% confidence interval), and the odds ratio and relative risk for each risk factor were calculated. Out of 34,355 search results, 96 records reporting the results from 102 studies fulfilled the inclusion criteria, representing 37 countries and all regions of the UN geoscheme. The global pooled prevalence of GORD was 13.98% and varied greatly according to region (12.88% in Latin America and the Caribbean to 19.55% in North America) and country (4.16% in China to 22.40% in Turkey). Using the United Nations 2017 Revision of World Population Prospects, the estimated number of individuals suffering from GORD globally is 1.03 billion. Multiple risk factors associated with a significant increase in the risk of GORD were also identified. This systematic review and meta-analysis revealed that although a substantial proportion (13.98%) of the global population suffers from GORD, there are significant variations between regions and countries. Risk factors for GORD were also identified which may allow clinicians to recognise individuals most at risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis

Nirwan

Hasan

Babar

et al. 2020

Sci Rep

194

148

View full text Add to dashboard Cite

show abstract

“…NSAIDs have been observed to cause increased gastric acidity, 26, 27 which could contribute to the upper GI symptoms that may occur with such therapy. Altered motility could also potentially be responsible, but the effects of NSAIDs on gastro‐oesophageal sphincter function and gastric emptying have been little studied and results are inconsistent 28, 29 . Thus, direct and indirect mucosal injury may be implicated in the development of some symptoms, and it is possible that the increased gastric acidity associated with NSAIDs results in increased oesophageal acid exposure and associated symptoms of heartburn and acid regurgitation.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non‐steroidal anti‐inflammatory drugs

Hawkey¹,

Jones

Yeomans

et al. 2006

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…While the effects of COX‐2 inhibitors on gastric mucosal integrity are the subjects of continued investigation, there is little information about the specific effects of these compounds on gastric emptying or small bowel transit in humans. Similarly, the effect of non‐selective COX inhibitors on gastric emptying are unclear as the literature suggests either no effect, an acceleration, or a delay in gastric emptying 12–15 …”

Section: Introductionmentioning

confidence: 99%

Effect of cyclooxygenase‐2 inhibitors on gastric emptying and small intestinal transit in humans

Bouras

Burton

Camilleri

et al. 2004

Neurogastroenterology Motil

View full text Add to dashboard Cite

Endogenous prostaglandins regulate smooth muscle activity; prostaglandins and cyclooxygenase (COX) inhibitors influence gastrointestinal motility in inflammatory states such as postoperative ileus in animal models. The objective of this study was to evaluate the effects of two COX-2 inhibitors on gastric emptying and intestinal transit in healthy humans. In a double-blind, placebo-controlled, parallel-group study, 66 healthy volunteers were randomized to one of two commercially available oral COX-2 inhibitors (celecoxib and rofecoxib), cisapride (positive control), or placebo. Following 7 days on therapy, study participants underwent a test of gastric emptying and small bowel transit of liquids and solids using scintigraphy. Data were analysed using Kruskal-Wallis (ANOVA on ranks)and Mann-Whitney rank sum tests. There were significant group effects on transit of solids: gastric emptying (ANOVA, P = 0.005) and small bowel transit (ANOVA, P = 0.056). However, neither COX-2 inhibitor significantly accelerated the liquid or solid gastric emptying or small bowel transit compared with placebo. The positive control, cisapride, accelerated gastric emptying of solids (post-lag slope of gastric emptying, P < 0.05), and small bowel transit of solids (t10%, P = 0.016). At maximum clinically approved dosages, celecoxib and rofecoxib have no significant effects on gastric emptying or small intestinal transit in healthy humans. Cisapride accelerates gastric emptying and small bowel transit in healthy humans.

show abstract

Gastric Emptying of Solids in Long-Term Nsaid Users: Correlation With Endoscopic Findings and Helicobacter Pylori Status

Abstract: Delayed gastric emptying was seen in 52% of patients on long-term NSAID therapy.

Cited by 12 publications

References 11 publications

Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis

Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis

Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non‐steroidal anti‐inflammatory drugs

Effect of cyclooxygenase‐2 inhibitors on gastric emptying and small intestinal transit in humans

Contact Info

Product

Resources

About